Bibliographic references for Probiotics for gut health

(1)Majeed, M., Nagabhushanam, K., Natarajan, S. et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 15, 21 (2015). https://doi.org/10.1186/s12937-016-0140-6

(2)Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009 Dec;31(10):655–9.

(3)Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench. 2014;7(3):156–63.

(4)Brenner DM, Chey WD. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev Gastroenterol Disord. 2009 Winter;9(1):7-15. PMID: 19367213.

(5)Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006 Jul;101(7):1581-90. doi: 10.1111/j.1572-0241.2006.00734.x. PMID: 16863564.

(6) Steven M Faber. September, 2000. Treatment of abnormal gut flora improves symptoms in patients with irritable bowel syndrome Elizabeth City, N.C., United States. A.Journal of Gastroenterology, 95(9):2533. 

(7) Kale‐Pradhan, P.B., Jassaly, H.K. and Wilhelm, S.M. (2010), Role of Lactobacillus in the Prevention of Antibiotic‐Associated Diarrhea: A Meta‐analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 30: 119-126. doi:10.1592/phco.30.2.119

(8). Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, Cammarota G, Anti M, De Lorenzo A, Pola P, Gasbarrini G, Gasbarrini A. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001 Feb;15(2):163-9. doi: 10.1046/j.1365-2036.2001.00923.x. PMID: 11148433.

(9) Cuentas, A.M., Deaton, J., Khan, S., Davidson, J., & Ardita, C.S. (2017). The Effect of Bacillus subtilis DE111 on the Daily Bowel Movement Profile for People with Occasional Gastrointestinal Irregularity. Journal of Probiotics & Health, 5, 1-4.

(10)Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009 Dec;31(10):655-9. doi: 10.1358/mf.2009.31.10.1441078. PMID: 20140275.

(11) Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol. 2009 Nov 18;9:85. doi: 10.1186/1471-230X-9-85. PMID: 19922649; PMCID: PMC2784472.

(12) Duc le H, Fraser PD, Tam NK, Cutting SM. Carotenoids present in halotolerant Bacillus spore formers. FEMS Microbiol Lett. 2006 Feb;255(2):215-24. doi: 10.1111/j.1574-6968.2005.00091.x. PMID: 16448498.

(13) Caulier S, Nannan C, Gillis A, Licciardi F, Bragard C, Mahillon J. Overview of the Antimicrobial Compounds Produced by Members of the Bacillus subtilis Group. Front Microbiol. 2019;10:302. Published 2019 Feb 26. doi:10.3389/fmicb.2019.00302

(14)Marseglia GL, Tosca M, Cirillo I, et al. Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther Clin Risk Manag. 2007;3(1):13-17. doi:10.2147/tcrm.2007.3.1.13

(15)Palaniyandi SA, Damodharan K, Suh JW, Yang SH. Probiotic Characterization of Cholesterol-Lowering Lactobacillus fermentum MJM60397 [published online ahead of print, 2019 Aug 20]. Probiotics Antimicrob Proteins. 2019;10.1007/s12602-019-09585-y. doi:10.1007/s12602-019-09585-y

(16)Vostalova J, Vidlar A, Simanek V, Galandakova A, Kosina P, Vacek J, Vrbkova J, Zimmermann BF, Ulrichova J, Student V. Are High Proanthocyanidins Key to Cranberry Efficacy in the Prevention of Recurrent Urinary Tract Infection? Phytother Res. 2015 Oct;29(10):1559-67. doi: 10.1002/ptr.5427. Epub 2015 Aug 13. PMID: 26268913.

(17)Vidlar A, Student V Jr, Vostalova J, Fromentin E, Roller M, Simanek V, Student V. Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study. World J Urol. 2016 Mar;34(3):419-24. doi: 10.1007/s00345-015-1611-7. Epub 2015 Jun 7. PMID: 26049866.

(18)Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011 Jul-Aug;2(4):256-61. doi: 10.4161/gmic.2.4.16108. Epub 2011 Jul 1. PMID: 21983070.

(19)Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012 Jul;34(3):255-62. doi: 10.4103/0253-7176.106022. PMID: 23439798; PMCID: PMC3573577.

(20)Schultz, Michael & Linde, Hans-Jörg & Lehn, Norbert & Zimmermann, Kurt & Grossmann, Johannes & Falk, Werner & Schölmerich, Jürgen. (2003). Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. The Journal of dairy research. 70. 165-73. 10.1017/S0022029903006034.

(21) Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057-1064. doi:10.3109/00365521.2011.584895

(22) Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001 Dec;74(6):833-9. doi: 10.1093/ajcn/74.6.833. PMID: 11722966.

(23) S., Latvala & S., Philipp & M.J., Lehtinen & Lehtoranta, Liisa & A.C., Ouwehand. (2019). Health Benefits of a Combination Probiotics; FlorMidabil™. International Journal of Probiotics and Prebiotics. 14. 9-17. 10.37290/ijpp2641-7197.14:9-17.

(24) West NP, Horn PL, Pyne DB, Gebski VJ, Lahtinen SJ, Fricker PA, Cripps AW. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014 Aug;33(4):581-7. doi: 10.1016/j.clnu.2013.10.002. Epub 2013 Oct 10. PMID: 24268677.

(24)Dubey AP, Rajeshwari K, Chakravarty A, Famularo G. Use of VSL[sharp]3 in the treatment of rotavirus diarrhea in children: preliminary results. J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S126-9. doi: 10.1097/MCG.0b013e31816fc2f6. PMID: 18806703.,

(25) Selinger CP, Bell A, Cairns A, Lockett M, Sebastian S, Haslam N. Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. J Hosp Infect. 2013 Jun;84(2):159-65. doi: 10.1016/j.jhin.2013.02.019. Epub 2013 Apr 22. PMID: 23618760.

(26) Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003 Apr 1;17(7):895-904. doi: 10.1046/j.1365-2036.2003.01543.x. PMID: 12656692.

(27)Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005 Oct;17(5):687-96. doi: 10.1111/j.1365-2982.2005.00695.x. PMID: 16185307.

(28)Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005 Jul;100(7):1539-46. doi: 10.1111/j.1572-0241.2005.41794.x. PMID: 15984978.

(29)Can, M., B. A. Besirbellioglu, I. Y. Avci, C. M. Beker, and A. Pahsa. “Prophylactic Saccharomyces Boulardii in the Prevention of Antibiotic-associated Diarrhea: A Prospective Study.” Medical Science Monitor 12.4 (2006): PI19-22.

(30) Kollaritsch, H., P. Kremsner, G. Wiedermann, and O. Schneider. “Prevention of traveller’s diarrhea: comparison of different non-antibiotic preparations.” Travel Med Int 11 (1989): 9-17.

(31)Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prophylaxe der Reisediarrhöe mit Saccharomyces boulardii. Ergebnisse einer plazebokontrollierten Doppelblindstudie [Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr Med. 1993 Mar 30;111(9):152-6. German. PMID: 8486328.

(32) Johnston, B. C., S. S.y. Ma, J. Z. Goldenberg, K. Thorlund, P. O. Vandvik, M. Loeb, and G. H. Guyatt. “Probiotics for the Prevention of Clostridium Difficile -Associated Diarrhea: A Systematic Review and Meta-analysis.” Annals of Internal Medicine 157.12 (2012): 878

(33)Moré MI, Vandenplas Y. Saccharomyces boulardii CNCM I-745 Improves Intestinal Enzyme Function: A Trophic Effects Review. Clin Med Insights Gastroenterol. 2018;11:1179552217752679. Published 2018 Feb 9. doi:10.1177/1179552217752679

(34)Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010 Jun;15(3):206-13. doi: 10.1111/j.1523-5378.2010.00751.x. PMID: 20557362.

(35)Paineau D, Carcano D, Leyer G, Darquy S, Alyanakian MA, Simoneau G, Bergmann JF, Brassart D, Bornet F, Ouwehand AC. 2008. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 53: 107-13.

(36)Ouewhand et al, (2009) ‘Specific probiotics alleviate allergic rhinitis during the birch pollen season’, World Journal of Gastronenterology, 15: 3261-3268.

(37)C.B. Wong, T. Odamaki, J. XiaoBeneficial effects of Bifidobacterium longum subsp. longum BB536 on human health: modulation of gut microbiome as the principal action J Funct Foods, 54 (2019), pp. 506-519

(38)Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009;15(17):1956-1973. doi:10.2174/138161209788453202

(39)Sudha MR, Jayanthi N, Aasin M, Dhanashri RD, Anirudh T (2018) Efficacy of Bacillus coagulans unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study. Benef Microb 9(4):563–572.

(40)Madempudi RS, Ahire JJ, Neelamraju J, Tripathi A, Nanal S. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. Sci Rep. 2019;9(1):12210. Published 2019 Aug 21. doi:10.1038/s41598-019-48554-x

(41)Ratna Sudha, M., Yelikar, K.A. & Deshpande, S. Clinical Study of Bacillus coagulans Unique IS-2 (ATCC PTA-11748) in the Treatment of Patients with Bacterial Vaginosis. Indian J Microbiol 52, 396–399 (2012). https://doi.org/10.1007/s12088-011-0233-z

(42)Ratna sudha, Madempudi & Bhonagiri, S.. (2012). Efficacy of Bacillus coagulans strain unique IS-2 in the treatment of patients with acute diarrhea. International Journal of Probiotics and Prebiotics. 7. 33-37.

(43)Madempudi, R.S., Neelamraju, J., Ahire, J.J. et al. Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study. Probiotics & Antimicro. Prot. 12, 335–342 (2020). https://doi.org/10.1007/s12602-019-09542-9

(44). Lönnermark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I. Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J Clin Gastroenterol. 2010 Feb;44(2):106-12. doi: 10.1097/MCG.0b013e3181b2683f. PMID: 19727002.

(45). Klarin, B., M. Wullt, I. Palmquist, G. Molin, A. Larsson, and B. Jeppsson. “Lactobacillus Plantarum 299v Reduces Colonisation of Clostridium Difficile in Critically Ill Patients Treated with Antibiotics.” Acta Anaesthesiologica Scandinavica 52.8 (2008): 1096-102.

(46). Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001 Oct;13(10):1143-7. doi: 10.1097/00042737-200110000-00004. PMID: 11711768.
(47). Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000 May;95(5):1231-8. doi: 10.1111/j.1572-0241.2000.02015.x. PMID: 10811333.

(48). Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-4018. doi:10.3748/wjg.v18.i30.4012

(49) Berggren A, Lazou Ahrén I, Larsson N, Önning G. Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. Eur J Nutr. 2011 Apr;50(3):203-10. doi: 10.1007/s00394-010-0127-6. Epub 2010 Aug 28. PMID: 20803023.

(50) Mori K, Ouchi K, Hirasawa N. The Anti-Inflammatory Effects of Lion’s Mane Culinary-Medicinal Mushroom, Hericium erinaceus (Higher Basidiomycetes) in a Coculture System of 3T3-L1 Adipocytes and RAW264 Macrophages. Int J Med Mushrooms. 2015;17(7):609-18. doi: 10.1615/intjmedmushrooms.v17.i7.10. PMID: 26559695.

(51)Dai X, Stanilka JM, Rowe CA, Esteves EA, Nieves C Jr, Spaiser SJ, Christman MC, Langkamp-Henken B, Percival SS. Consuming Lentinula edodes (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults. J Am Coll Nutr. 2015;34(6):478-87. doi: 10.1080/07315724.2014.950391. Epub 2015 Apr 11. PMID: 25866155.

(52) Knežević A, Živković L, Stajić M, Vukojević J, Milovanović I, Spremo-Potparević B. Antigenotoxic Effect of Trametes spp. Extracts against DNA Damage on Human Peripheral White Blood Cells. ScientificWorldJournal. 2015;2015:146378. doi:10.1155/2015/146378

(53)Gerasimov SV, Ivantsiv VA, Bobryk LM, Tsitsura OO, Dedyshin LP, Guta NV, Yandyo BV. Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: a randomized controlled trial. Eur J Clin Nutr. 2016 Apr;70(4):463-9. doi: 10.1038/ejcn.2015.171. Epub 2015 Oct 14. PMID: 26463725.

(54) Pakdaman MN, Udani JK, Molina JP, Shahani M. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance – a randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr J. 2016 May 20;15(1):56. doi: 10.1186/s12937-016-0172-y. PMID: 27207411; PMCID: PMC4875742.

(55) Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014 Jan;29(1):52-9. doi: 10.1111/jgh.12322. PMID: 23829297.

(56) Del Piano M, Carmagnola S, Anderloni A, Andorno S, Ballarè M, Balzarini M, Montino F, Orsello M, Pagliarulo M, Sartori M, Tari R, Sforza F, Capurso L. The use of probiotics in healthy volunteers with evacuation disorders and hard stools: a double-blind, randomized, placebo-controlled study. J Clin Gastroenterol. 2010 Sep;44 Suppl 1:S30-4. doi: 10.1097/MCG.0b013e3181ee31c3. PMID: 20697291.

(57)Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004 Jul;38(6 Suppl):S104-6. doi: 10.1097/01.mcg.0000129271.98814.e2. Erratum in: J Clin Gastroenterol. 2005 Mar;39(3):261. PMID: 15220671.

(58)Turner RB, Woodfolk JA, Borish L, et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomised controlled trial. Benef Microbes. 2017;8(2):207-215. doi:10.3920/BM2016.0160

(59)Black, F.T. & Andersen, Paul & Orskov, J. & Orskov, F. & Gaarslev, K. & Laulund, Svend. (1989). Prophylactic Efficacy of Lactobacilli on Traveler’s Diarrhea. Travel Med. 8. 333-335. 10.1007/978-3-642-73772-5_70.

(60) Alm L, Ryd-Kjellen E, Setterberg G, Blomquist L (1993). Effect of a new fermented milk product ‘CULTURA’ on constipation in geriatric patients. First Lactic Acid Bacteria Computer Conference Proceedings. Horizon Scientific Press, Norfolk, UK

(61Black F, Einarsson K, Lidbeck A, Orrhage K, Nord CE. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Scand J Infect Dis. 1991;23(2):247-54. doi: 10.3109/00365549109023408. PMID: 1906634.

(62)Whitehead A, Beck EJ, Tosh S, Wolever TM. Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014 Dec;100(6):1413-21. doi: 10.3945/ajcn.114.086108. Epub 2014 Oct 15. PMID: 25411276; PMCID: PMC5394769.

(63) Mölgaard J, von Schenck H, Olsson AG. Alfalfa seeds lower low density lipoprotein cholesterol and apolipoprotein B concentrations in patients with type II hyperlipoproteinemia. Atherosclerosis. 1987 May;65(1-2):173-9. doi: 10.1016/0021-9150(87)90019-0. PMID: 3606731.

(64)Ford AL, Nagulesapillai V, Piano A, Auger J, Girard SA, Christman M, Tompkins TA, Dahl WJ. Microbiota Stability and Gastrointestinal Tolerance in Response to a High-Protein Diet with and without a Prebiotic, Probiotic, and Synbiotic: A Randomized, Double-Blind, Placebo-Controlled Trial in Older Women. J Acad Nutr Diet. 2020 Apr;120(4):500-516.e10. doi: 10.1016/j.jand.2019.12.009. PMID: 32199523.

(65)Alm L, Ryd-Kjellen E, Setterberg G, Blomquist L (1993). Effect of a new fermented milk product ‘CULTURA’ on constipation in geriatric patients. 1st Lactic Acid Bacteria Computer Conference Proceedings. Horizon Scientific Press: Norfolk, England

(66)Fox MJ, Ahuja KDK, Robertson IK, et al Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study BMJ Open 2015;5:e006474. doi: 10.1136/bmjopen-2014-006474

(67)Lillian Jespersen, Inge Tarnow, Dorte Eskesen, Cathrine Melsaether Morberg, Birgit Michelsen, Susanne Bügel, Lars Ove Dragsted, Ger T Rijkers, Philip C Calder, Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in heal

(68)Szajewska H, Kołodziej M. Systematic review with meta-analysis: Lactobacillus  rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015 Nov;42(10):1149-57.

(69)Segers ME, Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG–host interactions. Microb Cell Fact. 2014 Aug 29;13 Suppl 1:S7.

(70)Rao R, Samak G. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. J Epithel Biol Pharmacol. 2012;5(Suppl 1-M7):47-54. doi:10.2174/1875044301205010047

(71)Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 2001;20(2 Suppl):149-156. doi:10.1080/07315724.2001.10719027

(72)Zamfir M, Callewaert R, Cornea PC, De Vuyst L. Production kinetics of acidophilin 801, a bacteriocin produced by Lactobacillus acidophilus IBB 801. FEMS Microbiol Lett. 2000;190(2):305-308. doi:10.1111/j.1574-6968.2000.tb09303.x

(73)Pakdaman MN, Udani JK, Molina JP, Shahani M. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance – a randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr J. 2016;15(1):56. Published 2016 May 20. doi:10.1186/s12937-016-0172-y

(74)Nagala, R. and c. Routray. 2011. “Clinical Case Study-Multispecies Probiiotic Supplement Minimizes Sysmtoms of Irritable bowel Syndrome.” US Gastroenterology & Hepatology Review

(75)Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus reuteri in Human Health and Diseases. Front Microbiol. 2018;9:757. Published 2018 Apr 19. doi:10.3389/fmicb.2018.00757

(76). Dennis-Wall, J. C., Culpepper T., Nieves C., Rowe C.C., Burns A.M., Rusch C.T., Federico A., Ukhanova M., Waugh S., Mai V., Christman M.C., and Langkamp-Henken B.. “Probiotics (Lactobacillus Gasseri KS-13, Bifidobacterium Bifidum G9-1, and Bifidobacterium Longum MM-2) Improve Rhinoconjunctivitis-specific Quality of Life in Individuals with Seasonal Allergies: A Double-blind, Placebo-controlled, Randomized Trial.” The American Journal of Clinical Nutrition 105.3 (2017): 758-67.

(77)Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463. doi:10.1016/j.vaccine.2013.11.053

By continuing to browse you agree to the storing of cookies on your device Cookie Policy

The cookie settings on this site are configured to "allow cookies" to provide you with the best possible browsing experience. If you continue to use this site without changing your cookie settings or clicking "Accept" you are consenting to this.

Close